Factors released in the TME, such as vascular endothelial growth factor (VEGF) or tumor-derived mediators, can impair the antigen-presenting ability of DCs, eventually suppressing their anti-tumoral activities [33,34]. The gene discussed is VEGFA; the disease is neoplasm.